Aura Renew Acq Regulatory News (ARA)

21 Dec 2006 07:00

Ardana PLC21 December 2006 Ardana plc (LSE: ARA) - voting rights and capital Edinburgh, UK, 21 December 2006; In conformity with the TransparencyDirective's transitional provision 6 we would like to notify the market of thefollowing: As at 21 December 2006, the issued share capital and voting rights of Ardana plcare as follows: Ardana plc's capital consists of 65,268,939 ordinary 1p shares with votingrights attached of one vote per ordinary share of which 12,681 ordinary sharesare held in Treasury. Therefore, the total number of voting rights in Ardana plc is 65,256,258. The above figure (65,256,258) may be used by shareholders as the denominator forthe calculations by which they will determine if they are required to notifytheir interest in, or a change to their interest in, Ardana plc under the FSA'sDisclosure and Transparency Rules. Enquiries For more information contact: Maureen Lindsay + 44 (0) 131 226 8550Ardana Julia Phillips/John Gilbert +44 (0)20 7831 3113Financial Dynamics(corporate and financial media relations) About Ardana Ardana plc is a pharmaceutical company focused on the discovery, development andmarketing of innovative products to improve human reproductive health, a $25.5billion market*. Since its foundation, Ardana has maintained a broad and balanced portfolio tomanage risk and actively pursues product and technology in-licensing andout-licensing to maintain a robust pipeline. Ardana's four lead products are summarised below: • Emselex(R), a once a day treatment for the symptoms of overactive bladder which Ardana has exclusive UK marketing and promotion rights and is being distributed in collaboration with Novartis Pharmaceuticals UK Limited; • StriantTM SR, a testosterone replacement therapy that has been launched by Ardana through its own sales force in the UK and through marketing partners in certain European countries, as a treatment for men with confirmed hypogonadism; • Invicorp, an injectable combination drug treatment for erectile dysfunction, for which Ardana has marketing and manufacturing rights in Europe; • Teverelix LA, in development for three initial indications (prostate cancer, BPH and endometriosis); • Testosterone Cream, a transdermal testosterone delivery system in development for the treatment of male hypogonadism, in Phase II trials; and • Oral GHS (EP01572) a oral growth hormone secretagogue in late stage development in the first indication for the diagnosis of growth hormone deficiency and in early stage development in a second indication. In addition, Ardana has a strong portfolio of follow-on products in development. Ardana is listed on the Main Market of the London Stock Exchange. For further information please see www.ardana.co.uk *Source: IMS Retail Drug Monitor November 2005. Statements contained within this press release may contain forward-lookingcomments which involve risks and uncertainties that may cause actual results tovary from those contained in the forward-looking statements. In some cases, youcan identify such forward-looking statements by terminology such as 'may', 'will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', 'estimates', 'predicts', 'potential', or 'continue'. Predictions andforward-looking references in this press release are subject to the satisfactoryprogress of research which is, by nature, unpredictable. Forward projectionsreflect management's best estimates based on information available at the timeof issue. This information is provided by RNS The company news service from the London Stock Exchange